Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

Antje Hoering, John Crowley, John D Shaughnessy, Jr, Klaus Hollmig, Yazan Alsayed, Jackie Szymonifka, Sarah Waheed, Bijay Nair, Frits van Rhee, Elias Anaissie, Bart Barlogie

Blood (2009) 114 (7): 1299–1305.

https://doi.org/10.1182/blood-2009-03-211953

Published: 2009

Journal Articles

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival

Bijay Nair, John D. Shaughnessy, Jr, Yiming Zhou, Marie Astrid-Cartron, Pingping Qu, Frits van Rhee, Elias Anaissie, Yazan Alsayed, Sarah Waheed, Klaus Hollmig, Jackie Szymonifka, Nathan Petty, Antje Hoering, Bart Barlogie

Blood (2009) 113 (26): 6572–6575.

https://doi.org/10.1182/blood-2009-02-207803

Published: 2009

Journal Articles

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

Bart Barlogie, Mauricio Pineda-Roman, Frits van Rhee, Jeff Haessler, Elias Anaissie, Klaus Hollmig, Yazan Alsayed, Sarah Waheed, Nathan Petty, Joshua Epstein, John D. Shaughnessy, Jr, Guido Tricot, Maurizio Zangari, Jerome Zeldis, Sol Barer, John Crowley

Blood (2008) 112 (8): 3115–3121.

https://doi.org/10.1182/blood-2008-03-145235

Published: 2008

Journal Articles

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

Bart Barlogie, Frits van Rhee, John D. Shaughnessy, Jr, Joshua Epstein, Shmuel Yaccoby, Mauricio Pineda-Roman, Klaus Hollmig, Yazan Alsayed, Antje Hoering, Jackie Szymonifka, Elias Anaissie, Nathan Petty, Naveen S. Kumar, Geetika Srivastava, Bonnie Jenkins, John Crowley, Jerome B. Zeldis

Blood (2008) 112 (8): 3122–3125.

https://doi.org/10.1182/blood-2008-06-164228

Published: 2008

Journal Articles

Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989

Bart Barlogie, Guido Tricot, Jeff Haessler, Frits van Rhee, Michele Cottler-Fox, Elias Anaissie, James Waldron, Mauricio Pineda-Roman, Raymond Thertulien, Maurizio Zangari, Klaus Hollmig, Abid Mohiuddin, Yazan Alsayed, Antje Hoering, John Crowley, Jeffrey Sawyer

Blood (2008) 111 (1): 94–100.

https://doi.org/10.1182/blood-2007-06-097444

Published: 2008

Journal Articles

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis

Frits van Rhee, Vanessa Bolejack, Klaus Hollmig, Mauricio Pineda-Roman, Elias Anaissie, Joshua Epstein, John D. Shaughnessy, Jr, Maurizio Zangari, Guido Tricot, Abid Mohiuddin, Yazan Alsayed, Gail Woods, John Crowley, Bart Barlogie

Blood (2007) 110 (3): 827–832.

https://doi.org/10.1182/blood-2007-01-067728

Published: 2007

Journal Articles

A Validated Gene Expression Signature of High Risk Multiple Myeloma Is Defined by Deregulated Expression of Genes Mapping to Chromosome 1.

John D. Shaughnessy, Jr., Fenghuang Zhan, Bart Burington, Yongsheng Huang, Ichiro Hanamura, James P. Stewart, Klaus Hollmig, Mauricio Pineda-Roman, Guido Tricot, Frits van Rhee, Maurizio Zangari, John Crowley, Bart Barlogie

Blood (2006) 108 (11): 111.

https://doi.org/10.1182/blood.V108.11.111.111

Published: 2006

Journal Articles

Total Therapies (TT) for Newly Diagnosed Patients with Multiple Myeloma (MM): Significant Benefit in High-Risk Disease with Cytogenetic Abnormalities (CA) over the Course of 17 Years.

Frits van Rhee, Vanessa Bolejack, Elias Anaissie, Guido Tricot, Klaus Hollmig, Maurizio Zangari, Mauricio Pineda-Roman, Abid Mohiuddin, Antje Hoering, John Crowley, Bart Barlogie

Blood (2006) 108 (11): 3490.

https://doi.org/10.1182/blood.V108.11.3490.3490

Published: 2006

Journal Articles

MRI and Metastatic Bone Survey (MBS) Examinations in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2.

Ronald Walker, MD, John Shaughnessy, PhD, Jeffery Haessler, MS, Joshua Epstein, DSc, Jeffery Sawyer, PhD, Elias J. Anaissie, MD, Frits Van Rhee, MD PhD, Guido Tricot, MD PhD, Maurizio Zangari, MD, Mauricio Pineda-Roman, MD, Klaus Hollmig, MD, John Crowley, MD, Bart Barlogie, MD PhD

Blood (2006) 108 (11): 3515.

https://doi.org/10.1182/blood.V108.11.3515.3515

Published: 2006

Journal Articles

Rapidly Cycled Aggressive Lymphoma-Like Therapy (HD-DTPACE) for Salvage of Patients with Advanced Multiple Myeloma (MM).

Varant Arzoumanian, MD, Bart Barlogie, MD,PhD, Mauricio Pineda-Roman, MD, Klaus Hollmig, MD, Elias Anaissie, MD, Maurizio Zangari, MD, Somashekar Krishna, MD, Eilas Kiwan, MD, Guido Tricot, MD,PhD, Abid Mohiuddin, MD, Frits van Rhee, MD,PhD

Blood (2006) 108 (11): 3561.

https://doi.org/10.1182/blood.V108.11.3561.3561

Published: 2006

Journal Articles

An Update on the Role of Thalidomide (THAL) in Total Therapy 2 (TT2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Analysis of Subgroups Defined by Standard Prognostic Factors (SPF) and Gene Expression Profiling (GEP)-Derived Subgroups.

John D. Shaughnessy, Jr., Jeffrey Haessler, Jerry Zeldis, Yongsheng Huang, Fenghuang Zhan, Jeffrey Sawyer, Elias Anaissie, Frits van Rhee, Guido Tricot, Joshua Epstein, Maurizio Zangari, Mauricio Pineda-Roman, Klaus Hollmig, John Crowley, Bart Barlogie

Blood (2006) 108 (11): 3389.

https://doi.org/10.1182/blood.V108.11.3389.3389

Published: 2006

Journal Articles

Testing Standard and Genetic Markers in 220 Patients with Multiple Myeloma (MM) with Complete Data Sets: Superiority of Molecular Genetics.

John D. Shaughnessy, Jr., Jeffrey Haessler, Ichiro Hanamura, Yongsheng Huang, James P. Stewart, Fenghuang Zhan, Jeffrey Sawyer, Elias Anaissie, Frits van Rhee, Guido Tricot, Joshua Epstein, Maurizio Zangari, Mauricio Pineda-Roman, Klaus Hollmig, John Crowley, Bart Barlogie

Blood (2006) 108 (11): 3391.

https://doi.org/10.1182/blood.V108.11.3391.3391

Published: 2006

Journal Articles

A Gene Expression Signature of Benign Monoclonal Gammopathy Evident in Multiple Myeloma Is Linked to Good Prognosis.

Fenghuang Zhan, Bart Barlogie, Varant Arzoumanian, Yongsheng Huang, Klaus Hollmig, Mauricio Pineda-Roman, Guido Tricot, Frits van Rhee, Maurizio Zangari, Madhav Dhodapkar, John D. Shaughnessy, Jr.

Blood (2006) 108 (11): 3393.

https://doi.org/10.1182/blood.V108.11.3393.3393

Published: 2006

Journal Articles

Focal Lesion (FL) Identification by MRI and Metastatic Bone Survey (MBS) in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2 (TT2).

Ronald Walker, Jeffrey Haessler, Guido Tricot, John D. Shaughnessy, Jr., Joshua Epstein, Jeffrey Sawyer, Elias Anaissie, Frits van Rhee, Maurizio Zangari, Mauricio Pineda-Roman, Klaus Hollmig, John Crowley, Bart Barlogie

Blood (2006) 108 (11): 3496.

https://doi.org/10.1182/blood.V108.11.3496.3496

Published: 2006

Journal Articles

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1

Blood (2006) 109 (6): 2276–2284.

https://doi.org/10.1182/blood-2006-07-038430

Published: 2006

Journal Articles

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis

Fenghuang Zhan, Bart Barlogie, Varant Arzoumanian, Yongsheng Huang, David R. Williams, Klaus Hollmig, Mauricio Pineda-Roman, Guido Tricot, Frits van Rhee, Maurizio Zangari, Madhav Dhodapkar, John D. Shaughnessy, Jr

Blood (2006) 109 (4): 1692–1700.

https://doi.org/10.1182/blood-2006-07-037077

Published: 2006

Includes: Supplemental data

Journal Articles

The molecular classification of multiple myeloma

Blood (2006) 108 (6): 2020–2028.

https://doi.org/10.1182/blood-2005-11-013458

Published: 2006

Includes: Supplemental data

Journal Articles

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation

Ichiro Hanamura, James P. Stewart, Yongsheng Huang, Fenghuang Zhan, Madhumita Santra, Jeffrey R. Sawyer, Klaus Hollmig, Maurizio Zangarri, Mauricio Pineda-Roman, Frits van Rhee, Federica Cavallo, Bart Burington, John Crowley, Guido Tricot, Bart Barlogie, John D. Shaughnessy, Jr

Blood (2006) 108 (5): 1724–1732.

https://doi.org/10.1182/blood-2006-03-009910

Published: 2006

Includes: Supplemental data

Journal Articles

Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies

Bart Barlogie, Guido Tricot, Erik Rasmussen, Elias Anaissie, Frits van Rhee, Maurizio Zangari, Athanasios Fassas, Klaus Hollmig, Mauricio Pineda-Roman, John Shaughnessy, Joshua Epstein, John Crowley

Blood (2006) 107 (7): 2633–2638.

https://doi.org/10.1182/blood-2005-10-4084

Published: 2006

Journal Articles

Total Therapy 2 (No Thalidomide Arm, TT2-) Is Superior to Total Therapy 1 (TT1) for Newly Diagnosed Multiple Myeloma (MM): Doubling 4-Yr Survival among Patients with Cytogenetic Abnormalities (CA) Due to Consolidation Chemotherapy (CCT) and DEX Maintenance.

Bart Barlogie, Guido Tricot, Erik Rasmussen, Elias Anaissie, Frits van Rhee, Maurizio Zangari, Klaus Hollmig, Teresa Milner, Joshua Epstein, John Shaughnessy, John Crowley

Blood (2005) 106 (11): 1152.

https://doi.org/10.1182/blood.V106.11.1152.1152

Published: 2005

NARROW

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis

A Validated Gene Expression Signature of High Risk Multiple Myeloma Is Defined by Deregulated Expression of Genes Mapping to Chromosome 1.

Total Therapies (TT) for Newly Diagnosed Patients with Multiple Myeloma (MM): Significant Benefit in High-Risk Disease with Cytogenetic Abnormalities (CA) over the Course of 17 Years.

MRI and Metastatic Bone Survey (MBS) Examinations in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2.

Rapidly Cycled Aggressive Lymphoma-Like Therapy (HD-DTPACE) for Salvage of Patients with Advanced Multiple Myeloma (MM).

An Update on the Role of Thalidomide (THAL) in Total Therapy 2 (TT2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Analysis of Subgroups Defined by Standard Prognostic Factors (SPF) and Gene Expression Profiling (GEP)-Derived Subgroups.

Testing Standard and Genetic Markers in 220 Patients with Multiple Myeloma (MM) with Complete Data Sets: Superiority of Molecular Genetics.

A Gene Expression Signature of Benign Monoclonal Gammopathy Evident in Multiple Myeloma Is Linked to Good Prognosis.

Focal Lesion (FL) Identification by MRI and Metastatic Bone Survey (MBS) in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2 (TT2).

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis

The molecular classification of multiple myeloma

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation

Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies

Total Therapy 2 (No Thalidomide Arm, TT2-) Is Superior to Total Therapy 1 (TT1) for Newly Diagnosed Multiple Myeloma (MM): Doubling 4-Yr Survival among Patients with Cytogenetic Abnormalities (CA) Due to Consolidation Chemotherapy (CCT) and DEX Maintenance.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only